The business scale continues to expand, and the revenue and net profit of Xinmai Medical will grow by nearly 50% in 2021 – yqqlm

On the evening of February 24th,Cardiovascular MedicineRelease 2021performanceExpress.During the reporting period, the company achieved a total operating income of 685 million yuan, an increase of 45.59% over the same period of the previous year;shareholderofnet profit316 million yuan, an increase of 47.30% over the same period of the previous year. At the end of the reporting period, the company’s total assets were 1.759 billion yuan, an increase of 27.83% over the beginning of the period; the owner’s equity attributable to the parent company was 1.495 billion yuan, an increase of 21.15% over the beginning of the period.

During the reporting period, although the COVID-19 epidemic has recurred, which has a certain impact on the development of related surgeries, the company’s innovative products include Castor branch aortic stent graft and delivery system, Minos abdominal aortic stent graft and delivery system, New products such as Reewarm PTX drug balloon dilatation catheter continue to grow rapidly, and the above products further consolidate and improve the company’s competitiveness in the aortic and peripheral vascular intervention market. At the same time, with the continuous expansion of the company’s innovative products in the international market, overseas business income has also achieved rapid growth.

In addition, during the reporting period, the company continued to adhere to technology research and development and innovation capacity building, and further increased investment in continuous research and development of innovative products.As of thisannouncementOn the day of disclosure, the company’s innovative products, Talos straight-tube thoracic aortic stent graft system and Fontus branch-type intraoperative stent system, have been awarded by the State Drug Administration.medical instrumentsRegistration certificate, the iliac vein stent system has completed all clinical enrollment and entered the special approval channel for innovative products. During the reporting period, the company’s R&D investment has increased significantly compared with 2020. At the same time, the company implemented an equity incentive plan during the reporting period, resulting in equity incentives The cost is nearly 5 million yuan.

(Article source: ShanghaisecuritiesNewspaper Chinasecuritiesnetwork)

Article source: Shanghai Securities News China Securities Network

Responsible editor: 3

Original title: The business scale continues to expand, and the revenue and net profit of Xinmai Medical will grow by nearly 50% in 2021